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Differential display polymerase chain reaction has
been used to isolate genes regulated in vascular endo-
thelial cells by the angiogenic factor vascular endothe-
lial cell growth factor (VEGF). Analysis of one of the
bands consistently up-regulated by VEGF led us to the
identification of a cDNA from a human umbilical vein
endothelial cell library that is 77% identical to the hu-
man K1-Cl2 cotransporter1 (KCC1). We have referred to
the predicted protein as K1-Cl2 cotransporter 3 (KCC3).
Hydrophobicity analysis of the KCC3 amino acid se-
quence showed an almost identical pattern to KCC1,
suggesting 12 membrane-spanning segments, a large ex-
tracellular loop with potential N-glycosylation sites, and
cytoplasmic N- and C-terminal regions. The KCC3 mRNA
was highly expressed in brain, heart, skeletal muscle,
and kidney, showing a distinct pattern and size from
KCC1 and KCC2. The KCC3 mRNA level in endothelial
cells increased on treatment with VEGF and decreased
with the proinflammatory cytokine tumor necrosis fac-
tor a, whereas KCC1 mRNA levels remained unchanged.
Stable overexpression of KCC3 cDNA in HEK293 cells
produced a glycoprotein of approximately 150 kDa,
which was reduced to 120 kDa by glycosidase digestion.
An increased initial uptake rate of 86Rb was seen in
clones with high KCC3 expression, which was depend-
ent on extracellular Cl2 but not Na1 and was inhibitable
by the loop diuretic agent furosemide. The KCC3
genomic localization was shown to be 15q13 by fluores-
cence in situ hybridization. Radiation hybrid analysis
placed KCC3 within an area associated with juvenile
myoclonic epilepsy. These results suggest KCC3 is a new
member of the KCC family that is under distinct regu-
lation from KCC1.
The cation chloride cotransporter (CCC)1 family is involved
in the electroneutral movement of ions across the plasma mem-
brane. There are three CCC subclasses identified thus far on
the basis of their structures, ligands, and inhibitors. These are
the thiazide-sensitive Na1-Cl2 cotransporters, the loop diuret-
ics-sensitive Na1-K1-Cl2 (NKCC), and the K1-Cl2 cotrans-
porters (KCC; Refs. 1–5). NKCC and KCC have two isotypes.
NKCC1 shows ubiquitous distribution (3) among organs,
whereas NKCC2 is restricted to kidney (2). KCC1 is ubiquitous
(4), whereas KCC2 is only found in brain (5). In addition to the
classical roles of transepithelial salt transport (6) and the reg-
ulation of cellular volume (7), Harling et al. (8) have recently
shown that tobacco protoplast growth becomes independent of
the plant hormone, auxin, when NKCC1 is overexpressed, sug-
gesting the possible involvement of the CCC family in cell cycle
regulation.
The physiological regulation of the NKCC and KCC family is
complex. Other than the electrochemical gradient of their li-
gands, evidence suggests that activation of this passive trans-
port system is regulated by phosphorylation (9), cytoskeletal
rearrangement (10), change of intracellular Mg21 concentra-
tion (6, 7), intracellular pH (11), oxygen concentration (12), and
cellular ATP levels (13). In addition, some stimuli can mediate
differential effects on various members of the CCC family. For
example, cell swelling activates KCC, whereas cell shrinkage
activates NKCC (6, 7). Phosphorylation activates NKCC,
whereas KCC is activated by dephosphorylation (6, 7). In cul-
tured endothelial cells, transcriptional regulation has been re-
ported for NKCC1 in response to sheer stress and proinflam-
matory cytokines (14). Cellular differentiation has also been
shown to be associated with changes in NKCC and KCC gene
expression. In the intestinal epithelial cell line HT29, a change
of NKCC1 mRNA level during differentiation has been re-
ported (15, 16), whereas the loss of K1-Cl2 flux during the
maturation of sheep red blood cells is well known (7).
We report here the isolation and cloning of a new member of
the KCC group of cotransporters, which we have named KCC3.
KCC3 displays high homology to KCC1, and the characteristics
of the ion flux mediated by KCC3 satisfies the criteria for a
KCC. KCC3 is regulated at the mRNA level by the angiogenic
factor VEGF and by the proinflammatory cytokine TNFa, nei-
ther of which has any effect on KCC1 mRNA levels. Finally,
KCC3 has been localized to chromosome 15q13, a region linked
to the inherited disease juvenile myoclonic epilepsy (17).
EXPERIMENTAL PROCEDURES
HUVECs—HUVECs were isolated as described previously (18). The
cells were cultured on gelatin-coated culture flasks in medium 199 with
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Eagle’s salts supplemented with 20% fetal calf serum. After passage 1,
the cells were grown in medium with 25 mg/ml endothelial cell growth
factor (Collaborative Research) and 25 mg/ml heparin (Sigma). For the
differential display, HUVECs were cultured in Opti-MEM medium (Life
Technologies, Inc.) with 2% fetal calf serum for 2 days.
Cytokine Stimulation—HUVECs grown to approximately 70% con-
fluency in Opti-MEM were stimulated with 50 ng/ml VEGF 165 (R & D
Systems) and 25 mg/ml heparin for 4 h. For TNFa stimulation, HUVECs
were grown in medium with 20% fetal calf serum and growth factor,
then treated for 4 h with 2 ng/ml TNFa (R & D).
Differential Display PCR—Primary culture HUVECs with or without
VEGF stimulation were lysed by Trizol reagent (Life Technologies,
Inc.). Total RNA was extracted using the manufacturer’s protocol and
was treated with RNA clean kit (Genhunter) to remove genomic DNA
contamination. The RNA obtained was reverse-transcribed using three
classes of anchor primers provided in the RNA Image Kit (Genhunter),
and each of three cDNA pools were amplified on the GeneAmp PCR
system 2400 model (Perkin-Elmer) with a combination of eight arbi-
trary primers and the same anchor primer used in reverse transcrip-
tion. This resulted in the generation of 24 amplicons from one RNA
sample. The primer-matched amplicons were electrophoresed side by
side in a 6% acrylamide gel. The bands that were consistently regulated
were retrieved from the gel, reamplified, and subcloned into a pGEM-T
vector (Promega) to be sequenced using Dye terminator cycle sequence
kit and the autosequencer (Perkin-Elmer-Applied Bio).
Cloning and Sequencing of KCC3—One of the bands consistently
up-regulated by VEGF treatment encoded a product whose DNA se-
quence was 90% identical to human KCC1. We used this sequence as a
probe (7AV1 probe) to screen a lgt10/HUVEC library (a gift from Dr.
Sawamura, Kyoto University). A 2.7-kb phage clone (clone 3) showed
significant homology to KCC1 (U55054 in GenBankTM/EBI data bank).
We further screened the library with a 59 sequence of clone 3 (3R probe,
a PCR product using primers 59-CATTGACGTTTGCTCTAAGACC and
59-GTTTGATCCAGCCATGATACC, see Fig. 2A) to obtain a 2.1-kb clone
(clone 9) that spanned a putative initiating ATG signal. Clone 3 and
clone 9 shared an overlap of 1 kb including a BstB1 site, which enabled
us to construct a 3.7-kb cDNA with an open reading frame for a 1099-
amino acid protein (see Fig. 2A, KCC3 protein, cDNA sequence depos-
ited in GenBankTM data base, accession number AF108831). Analysis of
the nucleic acid and amino acid sequences was carried out using the
programs provided by ANGIS (Australian National Genomic Informa-
tion Service).
Northern Blot Analysis—Total RNA was extracted from HUVECs of
primary and passaged cultures using Trizol reagent. Twenty mg of total
RNA was prepared and separated by electrophoresis in a 1% agarose gel
containing formaldehyde. RNA was transferred to Hybond N (Amer-
sham Pharmacia Biotech) membrane and UV-cross-linked. To produce
a specific KCC3 probe, we generated a 942-base pair PCR product using
KCC3-specific primers (GTCCCATCAAAGTTATG and GCAATAGCT-
TGTAGCAGCCTCG, corresponding to amino acids 349–548). This seg-
ment of cDNA was chosen because it had low homology to KCC1. After
purification of this product from agarose gel using Bresa Clean Kit
(Bresatec), the fragment was labeled with [32P]dATP (Giga label kit,
Bresatec) in the presence of 1 ng/ml reverse primer to replace the
random primers. To produce a KCC1-specific probe, TGGGACCATTT-
TCCTGACC and CATGCTTCTCCACGATGTCAC (corresponding to
amino acids 254–394) were used as forward and reverse primers, re-
spectively, and the same protocol was used. Hybridization was carried
out with ExpressHyb hybridization solution (CLONTECH). For study-
ing tissue-specific expression of KCC3, a human multiple tissue North-
ern blot (CLONTECH) was hybridized to the KCC3-specific probe.
Preparation of KCC3-overexpressing Transfectants—A FLAG
epitope-tagged full-length KCC3 cDNA expression construct was pro-
duced. By PCR, a FLAG sequence of DYKDDDDK was added to the N
terminus of KCC3 using the following primers (GAATTCATGGACTA-
CAAGGACGACGACGACAAGATGCCACATTTTACTGTGACT and
CTCCCTTGGGTAGGTAATTA (corresponding to amino acids 1–403).
The PCR generated a 1-kb PCR product that was digested with XhoI
and linked to the rest of the KCC3 sequence. The construct was intro-
duced into the pcDNA zeo 3.1 mammalian expression vector (Invitro-
gen), which was introduced to HEK293 cells using LipofectAMINE (Life
Technologies, Inc.). HEK293 cells were selected with 100 mg/ml zeocin
(Invitrogen), and colonies were picked to generate clonal populations.
Isotopic Flux Assays—Transfected HEK 293 cells were grown to
confluency in 24-well dishes coated with poly-D-lysine. Cells were
washed twice with flux medium (135 mM NaCl, 3 mM glucose, 5 mM
RbCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM Na2HPO4, 2 mM Na2SO4, 20 mM
HEPES, pH 7.4, and 0.1 mM ouabain) and then incubated for 15 min at
room temperature with 400 ml of flux medium containing 1 mM N-
ethylmaleimide (ICN). One hundred ml of flux medium containing 10
mCi/ml 86RbCl (Amersham Pharmacia Biotech) was quickly added.
Cells were incubated for 3 min before washing 3 times with ice-cold
phosphate-buffered saline. For sodium-free experiments, sodium was
replaced by N-methyl-D-glucamine (ICN), and for chloride-free experi-
ments, it was replaced by gluconate. Bumetanide (Sigma) and furo-
semide (Sigma) were administered at the indicated concentration at the
start of the preincubation with N-ethylmaleimide. Cells were lysed with
2% SDS and assayed for protein content using a BCA protein assay kit
(Pierce) and for 86Rb using Cerenkov radiation in a scintillation
counter.
Preparation of Anti-KCC3 Antibody and Protein Detection—Syn-
thetic KCC peptide 1 (SQNSITGEHSQLLDD) and peptide 2 (AIFHSD-
DALKESAA) were linked to chicken albumin (Sigma) to immunize
rabbits, and anti-KCC3 peptide antibodies (P1 antibody by peptide 1
and P2 antibody by peptide 2) were prepared as described previously
(19). To digest KCC3 protein by N-glycanase F (Boehringer Mannheim),
immunoprecipitated KCC3 was incubated with 250 milliunits/ml gly-
cosidase overnight at 30 °C in the presence of 10% Nonidet P-40.
Genomic Localization—The KCC3 coding sequence in the pGEM4Z
vector was nick-translated with biotin-14-dATP and hybridized in situ
at a final concentration of 15 ng/ml to metaphases from two normal
males. The fluorescence in situ hybridization method was modified from
that previously described (20). Chromosomes were stained before anal-
ysis with both propidium iodide (as counterstain) and 49,6-diamino-2-
phenylindole dihydrochloride (for chromosome identification). For the
radiation hybrid analysis, we performed a screen of a medium resolu-
tion Stanford G3 panel of 83 clones to refine the map position of the
KCC3 gene. PCR amplification was carried out on this panel using
primers g5 (TGCCACATTTTACTGTGAC) and g6 (TCATCTGAATCCT-
GAATCC), both of which lie in the 59 region of KCC3 gene. PCR results
were analyzed using the radiation hybrid mapping facility at the Stan-
ford Human Genome Center.
RESULTS
Isolation and Analysis of a KCC3 cDNA—In the differential
display PCR using total RNA extracted from 4-h VEGF-treated
HUVECs, a band was consistently up-regulated in experiments
using three independent pools of primary and passaged HU-
VECs as RNA sources. A representative example of these dif-
ferential displays is shown in Fig. 1. We have characterized
this product and generated a full-length cDNA from two over-
lapping clones (Fig. 2A). The cDNA sequence shows high ho-
mology to KCC1 and encodes a predicted protein of 1099 amino
acids. The primary amino acid sequence of this protein, which
we have named KCC3, is 77% identical to KCC1 and 73%
identical to KCC2 (Fig. 3). Five N-glycosylation consensus sites
are found in the large extracellular domain between the 5th
and 6th membrane-spanning regions (Fig. 3). The hydropathy
profile (by Kyte-Doolittle analysis) of KCC3 was almost iden-
tical to that of KCC1, predicting a protein with 12 membrane-
spanning segments and large intracellular N- and C-terminal
FIG. 1. Differential display PCR comparing VEGF-stimulated
and -unstimulated RNA populations. HT11A anchor primer and
AP7 arbitrary primer (RNA image kit, Genhunter) were used to amplify
cDNAs derived from primary HUVECs treated with VEGF (VEGF) or
without VEGF (ctrl). Amplicons from each group were applied in dupli-
cate. Consistently up-regulated bands are indicated by an arrow. Sim-
ilar up-regulation was seen in three other independent experiments.
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domains (Fig. 2B). Considerable diversity is seen, relative to
KCC1, in the N-terminal portion, the extracellular domain
between the 3rd and 4th membrane-spanning segments and
the 5th and 6th membrane-spanning segments and in the area
near the C terminus. KCC3 does not have a glutamic acid
residue at the beginning of the transmembrane domain 2. This
residue has been suggested to be important for the enhanced
extracellular potassium binding in KCC2 (21).
Expression and Regulation of KCC3 mRNA—Fig. 4A shows
the tissue-specific expression of KCC3. Unlike ubiquitously
expressed KCC1 and brain-restricted KCC2, strong expression
of KCC3 was observed in brain, heart, skeletal muscle, and
kidney. Transcripts of approximately 9, 7.5, and 4.5 kb were
detected (lanes 2, 3, 7, and 8 in Fig. 4A), and these showed
tissue-specific differences in abundance. KCC3 mRNA level
increased from as early as 1.5 h after VEGF administration,
whereas KCC1 levels remained unchanged (Fig. 4B). This was
true not only in primary HUVECs but also in passaged cells
(data not shown). We have also used semiquantitative PCR to
analyze the VEGF responsiveness and have obtained results
similar to the Northern blot data (not shown). It has been
reported that NKCC1 is up-regulated by TNFa (14); however,
the KCC3 mRNA level showed a down-regulation in response
to TNFa, whereas KCC1 remained unchanged (Fig. 4B).
Detection of KCC3 Protein in HUVECs and in HEK293
Cells—To further analyze the KCC3 gene product, we have
generated a KCC3 cDNA incorporating an N-terminal FLAG
epitope (N-FLAG KCC3). We have produced stable HEK293
cell lines overexpressing N-FLAG KCC3. The FLAG-tagged
protein, when immunoprecipitated with anti-FLAG antibody
(M2 antibody, Eastman Kodak Co.), was approximately150
kDa (Fig. 5A, lanes 1 and 2) and reduced to 120 kDa by diges-
tion with glycosidase treatment (Fig. 5B). Immunoprecipitation
using M2 antibody followed by Western blotting with anti-
KCC3 synthetic peptide 1 antibody (P1 antibody, Fig. 5A, lanes
3 and 4) and immunoprecipitation using P1 antibody followed
by Western blotting with M2 antibody (Fig. 5A, lanes 5 and 6)
gave the same results. These results were also reproduced
when we used P2 antibody instead of P1 antibody (data not
shown). KCC3 protein was also immunoprecipitated and blot-
ted from cultured HUVECs using P1 antibody (Fig. 5C).
Functional Characterization of KCC3—We used a 86Rb up-
take assay as a measure of K1 flux as described elsewhere (4).
When the FLAG sequence was added to the C terminus of
KCC3, there was no measurable difference in 86Rb uptake
between KCC3 clones and control populations (data not
shown). Therefore the N-FLAG KCC3 construct was used for
the functional analysis of KCC3. Expression of KCC3 in
HEK293 cells was confirmed after selection in zeocin by West-
ern blotting using M2 antibody. The results for 1 clone (clone
847) are shown in Fig. 6, although similar results were seen in
5 other independent clones (data not shown). A 3-min assay
was used because in both control and transfectants, 86Rb up-
take was linear at least for the initial 15 min (data not shown).
The results shown in Fig. 6B demonstrate a significantly in-
creased furosemide-sensitive 86Rb uptake in clone 847 that
expresses a high level of KCC3 (Fig. 6A). The magnitude of
furosemide-sensitive 86Rb uptake was similar to that reported
for KCC1 (4), because our value of 10 cpm/mg of protein/3 min
is equal to 3.2 nmol Rb/mg of protein/min. Such an increase was
not seen in clones that were zeocin-resistant but expressed a
low level of KCC3 (data not shown). The uptake was dependent
on extracellular Cl2 with little dependence on extracellular
Na1 (Fig. 6C). The loop diuretics furosemide and bumetanide
showed a dose-dependent inhibition of uptake with furosemide
slightly more effective than bumetanide (Ki of approximately10
mM versus 40 mM, Fig. 6D). The KCC3 transfectants did not
show a significant increase in 86Rb uptake in response to hy-
potonic treatment (data not shown). These results show that
KCC3 satisfies the functional criteria of the KCC class of
cotransporters.
Genomic Localization of KCC3—Twenty-five metaphases
from a normal male were examined for fluorescent signal. All of
these metaphases showed a signal on one or both chromatids of
chromosome 15 in the region 15q13 (Fig. 7). There was a total
of 2 nonspecific background dots observed in these 25 met-
aphases. A similar result was obtained from hybridization of
the probe to 15 metaphases from a second normal male (data
not shown). Radiation hybrid analysis indicated that KCC3 is
most closely associated with the chromosome 15 marker
SHGC-33497 with a LOD score of 1000. Assessment of flanking
markers D15S1010 and D15S1040, using the integrated gene
maps available at NCBI, gave a result consistent with the
localization of KCC3 by fluorescence in situ hybridization
analysis.
FIG. 2. Schematic diagram of se-
lected clones encoding KCC3 and a
predicted hydropathy profile. Panel
A, map of KCC3 cDNA. Clone 3 and clone
9 have an overlap of 1 kb that contains a
BstBI site used to construct a 3767-bp
KCC3 cDNA. The coding region of KCC3
(3297 bp) is shown by the filled box. The
location of the two probes used for screen-
ing is shown (3R and 7AV1). Panel B,
hydropathy profiles of KCC3 and KCC1.
KCC3 and KCC1 peptide sequences were
analyzed using the Kyte-Doolittle algo-
rithm in the PEPPROT program at
ANGIS.
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DISCUSSION
We describe here the cloning of a new member of the CCC
family that is structurally closely related to the potassium chlo-
ride cotransporter KCC1 and that we therefore have named
KCC3. The amino acid sequence shows significant homology to
other KCC family members with overall amino acid identity
between KCC1 and KCC3 being 77%. There is a large predicted
extracellular domain between the 5th and 6th putative mem-
brane-spanning regions that is common to the KCC family but
not observed in the NKCC family. Considerable diversity is ob-
served in the N-terminal portion and in the extracellular do-
mains between the 3rd and 4th and 5th and 6th putative mem-
brane-spanning segments (Fig. 3). It is also notable that there are
four deletions in the C-terminal region common to KCC1 and
KCC3 that are not present in KCC2 (Fig. 3). The C-terminal
conserved portion appears important in its function as addition of
a FLAG epitope to the C terminus of KCC3 abolished the uptake
of 86Rb in our assay (data not shown). Furthermore, Harling et al.
(8) find that the C-terminal fragment of AXI 4, a plant CCC, is
sufficient for establishing auxin-independent growth of tobacco
protoplast growth.
Overexpression of KCC3 in HEK293 cells allowed functional
analysis and demonstrated that KCC3 exhibits characteristics
expected of a KCC. 86Rb flux was significantly increased in
KCC3 transfectants. This increase was independent of extra-
cellular Na1 but dependent on extracellular Cl2. This and the
fact that the 86Rb flux was measured in the presence of the
SH-reactive reagent N-ethylmaleimide (22), which inhibits
NKCC1 but activates KCC (4), suggest that NKCC1 is not a
major contributor in our assay. It is also considered unlikely
that KCC1 is responsible for all the 86Rb uptake observed in
the transfectants, because increased uptake was only seen in
clones expressing high levels of KCC3. Furthermore, in both
KCC3-expressing transfectants and control transfectants, the
mRNA levels of KCC1 were equivalent (data not shown).
Analysis of multiple tissue blot Northern filters probed with
a KCC3-specific probe showed a tissue-specific expression pat-
tern with highest levels observed in kidney, skeletal muscle,
heart, and brain. This contrasted with the expression of KCC1,
which is ubiquitous (4), and KCC2, which is restricted to brain
(5). Although the reason for the selective tissue distribution is
unknown, it suggests that KCC3 does not serve a general
housekeeping function such as cell volume regulation as has
been proposed for KCC1 (4). This is further supported by the
lack of detectable regulation of KCC3 activity in response to
alterations in osmolarity (data not shown).
At present we do not know the role of KCC3 in endothelial
FIG. 4. Distribution and regulation of the KCC3 mRNA. Panel
A, tissue-specific expression of KCC3 mRNA. A multiple tissue North-
ern blot membrane (CLONTECH) was probed with a KCC3-specific
probe. Lane 1, pancreas; lane 2, kidney; lane 3, skeletal muscle; lane 4,
liver; lane 5, lung; lane 6, placenta; lane 7, brain; lane 8, heart. Molec-
ular size (kb) is indicated on the left. Panel B, regulation of KCC3
mRNA level by VEGF and TNFa treatment. Primary culture HUVECs
were treated for 1.5 h with (VEGF) or without (ctrl) VEGF. Passaged
HUVECs were treated for 4 h with (TNFa) or without (ctrl) TNFa. Each
membrane was probed with KCC3, KCC1, and : glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) probes in that order. The increase of the
KCC3 mRNA observed by treatment with VEGF is 1.8-fold, and the
decrease by TNFa is 52%. Two other experiments showed similar
results.
FIG. 5. Analysis of the KCC3 protein. Panel A, detection of the
KCC3 protein in HEK293 cells overexpressing KCC3 (clone 847). Cells
were lysed, and the KCC3 protein was immunoprecipitated using anti-
FLAG M2 antibody and blotted with M2 (lanes 1 and 2) or anti-KCC3
synthetic peptide1 antibody (P1 antibody, see “Experimental Proce-
dures,” lanes 3 and 4). In lanes 5 and 6, KCC3 was immunoprecipitated
with P1 antibody and blotted with M2 antibody. HEK293 cells overex-
pressing KCC3 were used in lanes 1, 3, and 5, and control HEK293 cells
were used in lanes 2, 4, and 6. Panel B, glycosylation of KCC3 protein.
KCC3 was immunoprecipitated from clone 847 cells with M2 antibody
and digested overnight with N-glycosidase F. F2, before digestion; F1,
after digestion. Panel C, detection of the endogenous KCC3 protein in
HUVECs. Passage 3 HUVECs were lysed, and the KCC3 protein was
immunoprecipitated with control antibody (lane 1) or P1 antibody (lane
2) followed by Western blotting with P1 antibody.
FIG. 3. Comparison of the primary structures of the KCC family members. Identical amino acids are shaded. Predicted transmembrane
segments are highlighted by lines above the KCC3 sequence. Consensus motifs for N-glycosylation sites (Gly), casein II kinase phosphorylation
sites (C), and protein kinase C phosphorylation sites (PK) are also shown above the sequence. Multiple sequence alignment was performed using
the PILEUP and PRETTY BOX programs (ANGIS), and consensus sites were identified with the MOTIF program at ANGIS.
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cells. However, the responsiveness of this gene in HUVECs to
VEGF suggests an involvement in angiogenesis. It is tempting
to speculate that the up-regulation of KCC3 mRNA levels me-
diated by VEGF may be through modulation of the cytoskele-
ton, which results in changes in cell shape (23). Such changes
have been reported to be one of the initial events upon angio-
genic stimulation (24), and changes of this type can also affect
the expression of the CCC members (7). Recently Edwards et
al. (25) reported that K1 released from endothelial cells in
response to acetylcholine stimulation caused hyperpolarization
and relaxation of smooth muscle cells through activation of the
Na-K-ATPase and Ba21-sensitive K1 channel. Thus K1 may
also be important in the control of blood pressure. Because the
Na-K-ATPase generates the chemical gradient that drives
CCCs, it also implies that KCC3 may be involved in modulating
the local K1 concentration.
We also observed a down-regulation of the KCC3 mRNA
level in response to TNFa. Because NKCC1 is up-regulated by
TNFa (14), our results suggest that KCC3 may be a functional
counterpart of NKCC1. Certainly KCC1 mRNA levels showed
no change in response to TNFa, supporting the idea that KCC3
and NKCC1 are coregulated in response to TNFa. NKCC1 has
been reported to play a role downstream of the growth hormone
auxin in tobacco protoplasts (8), where it is involved in cell
cycle progression; therefore we speculate that KCC3 may also
be involved in cell cycle regulation. Interestingly, the tissue-
specific expression pattern of KCC3 resembles that of cyclin G1
(26), a cyclin involved in cell cycle arrest.
KCC3 has been localized to 15q13 and between the genetic
markers D15S1010 and D15S1040. This region has recently
been linked to juvenile myoclonic epilepsy (17), raising the
possibility that KCC3 is a candidate gene for this disease.
FIG. 6. Functional analysis of KCC3. Panel A, expression of the KCC3 protein in clone 847 cells. KCC3 was immunoprecipitated from either
clone 847 (lane 1) or control cells (lane 2) by M2 antibody followed by Western blotting with P1 antibody. Panel B, demonstration of enhanced 86Rb
uptake by KCC3-transfected HEK293 cells. HEK293 cells, HEK293 cells transfected with blank vector (CTRL), and clone 847 were assayed for
their 86Rb uptake after preincubation with 1 mM N-ethylmaleimide. Values after subtracting furosemide-insensitive 86Rb uptake are shown.
Values are shown as mean 6S.D. (n 5 3). Two other experiments showed similar results. Panel C, extracellular Na1 independence and Cl2
dependence of KCC3. Clone 847 cells were assayed for furosemide-sensitive 86Rb uptake in the absence of extracellular Na1 (Na2) or Cl2 (Cl2,
n 5 3). See “Experimental Procedures” for details. Values are shown as mean 6S.D. Two other experiments showed similar results. Panel D,
sensitivity for loop diuretic agents. Percent decrease of 86Rb uptake of clone 847 cells by incremental concentration of furosemide (closed circle) and
bumetanide (open circle) are shown (n 5 3). Values are shown as mean 6S.D. Two other experiments showed similar results.
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Payne (21) has postulated that KCC2, a brain-restricted KCC,
acts as a neuronal Cl2 pump, complementing other systems in
regulating K1 homeostasis. The concept is now emerging that
the idiopathic epilepsies may represent ion channel disorders
(27) based on certain inherited forms of epilepsy in mice (28),
mutations in the a4 subunit of neuronal nicotinic acetylcholine
receptor responsible for autosomal dominant nocturnal frontal
lobe epilepsy (29), and benign familial neonatal convulsions
because of mutations of potassium channel gene (30–32). Thus,
we suggest that KCC3 may be a candidate gene for juvenile
myoclonic epilepsy worthy of further investigation.
Acknowledgments—We thank Dr. Yutaka Tagaya (NIH, Bethesda,
MD) for practical advice on performing differential display PCR and
interpretation of its pattern and Professor David Cook (Sydney Univer-
sity) and Dr. Peter Little (Baker Institute Melbourne) for helpful ad-
vice. We also thank the staff at the delivery rooms of the Women’s and
Children’s Hospital and Burnside War Memorial Hospital Adelaide for
collection of umbilical cords.
REFERENCES
1. Gamba, G., Saltzberg, S. N., Lombardi, M., Miyanoshita, A., Lytton, J., Hedi-
ger, M. A., Brenner, B. M., and Herbert, S. C. (1993) Proc. Natl. Acad. Sci.
U. S. A. 90, 2749–2753
2. Gamba, G., Miyanoshita, A., Lombardi, M., Lytton, J., Lee, W. S., Hediger,
M. A., and Herbert, S. C. (1994) J. Biol. Chem. 269, 17713–17722
3. Xu, J. C., Lytle, C., Zhu, T. T., Payne, J. A., Benz, E., Jr., and Forbush, B., III
(1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2201–2205
4. Gillen, C. M., Brill, S., Payne, J. A., and Forbush, B. III. (1996) J. Biol. Chem
271, 16237–16244
5. Payne, J. A., Stevenson, T. J., and Donaldson, L. F. (1996) J. Biol. Chem. 271,
16245–16252
6. Haas, M. (1994) Am. J. Physiol. 267, C869–C885
7. Lauf, P. K., Bauer, J., Adragna, N. C., Fujise, H., Zade-Oppen, A. M. M., Ryu,
K. H., and Delpire, E. (1992) Am. J. Physiol. 263, C917–C932
8. Harling, H., Czaja, I., Shell, J., and Walden, R. (1997) EMBO J. 16 5855–5866
9. Krarup, T. Jakobsen, L. D., Jensen, B. S., and Hoffmann, E. K. (1998) Am. J.
Physiol. 275, C239–C250
10. Matthews, J. B., Awtrey, C. S., and Madara, J. L. (1992) J. Clin. Invest. 90,
1608–1613
11. Zade-Oppen, A. M. M., and Lauf, P. K. (1990) J. Membr. Biol. 118, 143–151
12. Gibson, J. S., Speake, P. F., and Ellory, J. C. (1998) J. Physiol. (Lond.) 511,
225–234
13. Lauf, P. K. (1983) Am. J. Physiol. 245, C445–C448
14. Topper, J. N., Wasserman, S. M., Anderson, K. R., Cai, J., Falb, D., and
Gimbrone, M. A., Jr. (1997) J. Clin. Invest. 99, 2941–2949
15. Matthews, J. B., Hassan, I., Meng, S., Archer, S. Y., Hrnjez, B. J., and Hodin,
R. A. (1998) J. Clin. Invest. 101, 2072–2079
16. Moore-Hoon, M. L., and Turner, R. J. (1998) Biochem. Biophys. Res. Commun.
244, 15–19
17. Elslie, F. V., Rees, M., Williamson, M. P., Kerr, M., Kjeldsen, M. J., Pang, K. A.,
Sundqvist, A., Mo¨gens, L. F., Chadwick, D., Richens, A., Covanis, A., Santos,
M., Arzimanoglou, A., Panayiotopoulos, C. P., Curtis, D., Whitehouse, W. P.,
and Gardiner, R. N. (1997) Hum. Mol. Genet. 6, 1329–1334
18. Wall, R. T., Harker, L. A., Quadracci, L. J., and Striker, G. E. (1978) J. Cell.
Physiol. 96, 203–213
19. Tomiyama, S, and Andoh, T. (1987) Manual for Monoclonal Antibody, pp.
178–179, Kodansha Scientific, Tokyo
20. Callen, D. F., Baker, E., Eyre, H. J., Chernos, J. E., Bell, J. A., and Sutherland,
G. R. (1990) Ann. Genet. 33, 219–221
21. Payne, J. A. (1997) Am. J. Physiol. 273, C1516–C1525
22. Kramhoft, B., Lambert, I. H., Hoffman, E. K., and Jorgensen, F. (1986) Am. J.
Physiol. 251, C369–C379
23. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., and Heldin,
C.-H. (1994) J. Biol. Chem. 269, 26988–26995
24. Folkman, J., and Shing, Y. (1992) J. Biol. Chem 267, 10931–10934
25. Edwards, G., Dora, K. A., Gardener, M. J., Garland, C. J., and Weston, A. H.
(1998) Nature 396, 269–272
26. Horne, M. C., Goolsby, G. L., Donaldson, K. L., Tran, D., Neubauer, M., and
Wahl, A. F. (1996) J. Biol. Chem. 271, 6050–6061
27. Steinlein, O. K. (1998) Clin. Genet 54, 169–175
28. Flethcer, C. F., Lutz, C. M., O’Sullivan, T. N., Shaughnessy, J. D., Jr., Hawkes,
R., Frankel, W. N., Copeland, N. G., and Jenkins, N. A. (1996) Cell 87,
607–617
29. Steinlein, O. K., Mulley, J. C., Propping, P., Wallace, R. H., Phillips, H. A.,
Sutherland, G. R., Scheffer, I. E., and Berkovic, S. F. (1995) Nat. Genet. 11,
201–203
30. Biervert, C., Schroeder, B. C., Kubisch, C., Berkovic, S. F., Propping, P.,
Jentsch, T. J., and Steinlein, O. K. (1998) Science 279, 403–406
31. Charlier, C., Singh, N. A., Ryan, S. G., Lewis, T. B., Reus, B. E., Leach, R. J.,
and Leppert, M. (1998) Nat. Genet. 18, 53–55
32. Singh, N. A., Charlier, C., Stauffer, D., Dupont, B. R., Leach, R. J., Melis, R.,
Ronen, G. M., Bijerre, I., Quattlebaum, T., Murphy, J. V., McHarg, M. L.,
Gagnon, D., Rosales, T. O., Peiffer, A., Anderson, V. E., and Leppert, M.
(1998) Nat. Genet. 18, 25–29
FIG. 7. Fluorescence in situ hybridization analysis with a
KCC3 probe. Normal male chromosomes were stained with propidium
iodide and 49,6-diamino-2-phenylindole dihydrochloride before hybrid-
ization with a KCC3 probe. This is a single metaphase spread of 40 that
were analyzed. All showed a similar hybridization pattern. Hybridiza-
tion sites on chromosome 15 are indicated by arrows.
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